lindis bloodcare
Lindis Bloodcare develops CATUVAB, a medical device designed to remove tumor and immune cells from salvaged blood during oncological surgeries. Utilizing proprietary Antibody-Based Cell Removal Technology (ABCR-T), the device enables the safe retransfusion of a patient’s own blood to reduce reliance on donor blood and avoid associated side effects. The company targets the surgical healthcare market, specifically focusing on 14 major tumor indications where intraoperative blood salvage was previously restricted.
Visit websiteHennigsdorf, Germany
Healthtech
MedTech
Biotechnology
Medical Devices
Funding summary
- Total raised
- €5.0M
- Funding rounds
- 1
Investors in lindis bloodcare
Investors on record for lindis bloodcare. Click any investor to view their CAPLINK profile and funding criteria.
Fundraising for a startup like lindis bloodcare?
Explore CAPLINK's investor database of thousands of active VCs and angels.
Browse investors